Poor metabolizer genotype status of CYP2C19 is a risk factor for developing gastric cancer in Japanese patients with Helicobacter pylori infection
Open Access
- 21 October 2005
- journal article
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 22 (10), 1033-1040
- https://doi.org/10.1111/j.1365-2036.2005.02678.x
Abstract
Summary: Background : Cytochrome P450 2C19 (CYP2C19) polymorphism has been associated with the development of lung, liver or oesophageal cancer by detoxification of carcinogen(s) or activation of procarcinogen(s).Aim: To clarify the association between CYP2C19 polymorphisms and gastric cancer development in Japanese.Methods : We determined CYP2C19 genotypes (CYP2C19*1, *2 and *3) in 111 Helicobacter pylori‐positive patients with gastric cancer and 315 H. pylori‐positive controls without gastric cancer consisting of patients with gastritis only or peptic ulcer. Frequencies of CYP2C19 genotypes and serum pepsinogen I and II levels, a biomarker of gastric atrophy, in the gastric cancers and controls were compared.Results : Frequencies of homozygous extensive metabolizers, heterozygous extensive metabolizers and poor metabolizers were 31.5%, 42.3% and 26.2% in the gastric cancers and 38.1%, 47.0% and 14.9% in the controls, respectively (P = 0.046). Poor metabolizers were associated with an increased risk for developing gastric cancer with the age‐ and sex‐adjusted odds ratio (OR) of 1.975 [95% confidence interval (CI): 1.068–3.649], especially for diffuse type (OR: 3.385, CI: 1.187–9.648). There is no significant association between CYP2C19 genotypes and serum pepsinogen I level or pepsinogen I/II ratios, although serum pepsinogen I level in gastric cancers were significantly decreased.Conclusions : In H. pylori‐positive Japanese, poor metabolizers of CYP2C19 appear to be at an increased risk for developing gastric cancer, especially diffuse type, and may require an intensive follow‐up for scrutinizing possible gastric cancer development.Keywords
This publication has 34 references indexed in Scilit:
- Relationship between genetic polymorphisms of drug-metabolizing enzymes ( CYP1A1 , CYP2E1 , GSTM1 , and NAT2 ), drinking habits, histological subtypes, and p53 gene point mutations in Japanese patients with gastric cancerThe Esophagus, 2004
- Polymorphism of interleukin-1β affects the eradication rates of Helicobacter pylori by triple therapyClinical Gastroenterology and Hepatology, 2004
- Helicobacter pyloriInfection and the Development of Gastric CancerNew England Journal of Medicine, 2001
- Genotype analysis of the CYP2C19 gene in HCV-seropositive patients with cirrhosis and hepatocellular carcinomaLife Sciences, 2000
- Interleukin-1 polymorphisms associated with increased risk of gastric cancerNature, 2000
- Expression of Cytochrome P450 3A4 in Foveolar Epithelium with Intestinal Metaplasia of the Human StomachJapanese Journal of Cancer Research, 1998
- Genotype analysis of the CYP2C19 gene in the Japanese populationLife Sciences, 1996
- Interethnic Differences in Omeprazole Metabolism in the Two S-Mephenytoin Hydroxylation Phenotypes Studied in Caucasians and OrientalsTherapeutic Drug Monitoring, 1994
- Clinical Application of Serum Pepsinogen I and II Levels for Mass Screening to Detect Gastric CancerJapanese Journal of Cancer Research, 1993
- Omeprazole Drug Interaction StudiesClinical Pharmacokinetics, 1991